Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

Septic Shock Clinical Trial

Official title:

Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01648036
• Other study ID #: HCA2011/001
• Status: Completed
• Phase: Phase 2
• First received: July 14, 2012
• Last updated: July 9, 2014
• Start date: July 2012
• Est. completion date: February 2014

Study information

• Verified date: July 2014
• Source: University of Manitoba
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Life-threatening infections account for 10% of all intensive care unit admissions and constitute the second more frequent cause of death in the ICU after heart diseases. The most common cause of death in patients admitted with life-threatening infections is multi-organ failure that is mediated by severe inflammation. Given the relationship between inflammation and blood clotting, blood-thinners (also called anticoagulants) have been used to decrease inflammation and the formation of small clots. Several lines of evidence suggest that heparin, a proven and inexpensive blood-thinner, may reduce improve survival in patients diagnosed with life-threatening infection. The primary objective of this study is to demonstrate the feasibility of enrolling patients in a large randomized controlled trial investigating heparin in patients with severe infections. In this study, patients with life-threatening infections will have an equal chance of receiving an intravenous infusion of heparin, or a low dose of a similar drug to prevent of blood clots while patients are immobile. The primary purpose of the study is to demonstrate that an average of 2 patients per site, per month, can be enrolled. Other measures of feasibility include the consent rate, the number of protocol violations that occur during the trial, and the number of dose reductions needed due to excessive anticoagulation. To study the biologic effects of heparin in patients with severe infection, specific laboratory markers will be measured and analyzed. If the feasibility of the trial is confirmed, a large randomized trial designed to tell if heparin can safely improve survival will be conducted. Given its low cost and availability, if heparin is shown to improve survival in patients with severe infection, adoption of this therapy on a global scale is anticipated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: February 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. = 18 years of age

2. Refractory hypotension documented within 36 hours prior to enrolment that requires institution and ongoing use of vasopressor agents (phenylephrine, norepinephrine, vasopressin, epinephrine, or dopamine > 5 mcg/kg/min) at the time of enrolment. Refractory hypotension is defined as a systolic blood pressure < 90 mmHG or a systolic blood pressure more than 30 mmHg below baseline, or a mean arterial pressure less than 65 mmHG and receipt of greater than or equal to 2 litres of intravenous fluid for the treatment of hypotension.

3. At least 1 other new organ dysfunction defined by the following:

• Creatinine = 150 µmol/L, or = 1.5x the upper limit of normal or the known baseline creatinine, or < 0.5 ml/kg or urine output for 2 hours(Patients on chronic hemodialysis or peritoneal dialysis must meet one of the following criteria)

• Need for invasive mechanical ventilation or a P/F ratio < 250

• Platelets < 100 x109/L, or a drop of 50 x109/L in the 3 days prior to enrollment

• Arterial pH < 7.30 or base deficit > 5 mmol/L in association with a lactate >/= to 3.0 mmol/L

Exclusion Criteria:

1. Consent declined

2. Clinically apparent other forms of shock including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponnade, tension pneumothorax), hemorrhagic, neurogenic, or anaphylactic

3. Received vasopressor therapy for greater than 36 hours prior to enrollment

4. Have a significant risk of bleeding as evidenced by one of the following:

• Clinical: Surgery requiring general or spinal anesthesia within 24 hours prior to enrollment, or the potential need for such surgery in the next 24 hours; evidence of active bleeding; a history of severe head trauma requiring hospitalization; intracranial surgery, or stroke within 3 months before the study or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system; a history of congenital bleeding diatheses; gastrointestinal bleeding within 6 weeks before the study unless corrective surgery had been performed; trauma considered to increase the risk of bleeding; presence of an epidural catheter

• Laboratory: Platelet count < 30 x109/L, INR > 2.0, or baseline aPTT > 50 sec prior to enrollment.

5. Have an indication for therapeutic anticoagulation (e.g. ACS, acute VTE, mechanical valve, etc)

6. Intent of the most responsible physician to prescribe rhAPC

7. Have had a known or suspected adverse reaction to UFH including HIT

8. Are currently enrolled in related trial

9. Known or suspected cirrhosis, or chronic ascites

10. Use of any of the following medications or treatment regimens: unfractionated heparin to treat an active thrombotic event within 12 hours before the infusion enrollment; low-molecular-weight heparin at a higher dose than recommended for prophylactic use (as specified in the package insert) within 12 hours before the infusion; warfarin (if used within 7 days before study entry AND if the INR time exceeded the upper limit of the normal range for the institution); thrombolytic therapy within 3 days before the study, glycoprotein IIb/IIIa antagonists within 7 days before study entry; protein C or rhAPC within 24 hours before enrollment.

11. Terminal illness with a life expectancy of less than 3 months

12. Are pregnant

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Septic Shock
• Shock
• Shock, Septic

Intervention

Drug:
• Unfractionated heparin
Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
• Dalteparin
Dose 5000 IU, subcutaneous, daily

Locations

Country	Name	City	State
Canada	Capital Health - Queen Elizabeth II Health Sciences Centre	Halifax	Nova Scotia
Canada	Hamilton General Hospital	Hamilton	Ontario
Canada	St Joseph's Healthcare Hamilton	Hamilton	Ontario
Canada	Ottawa Hospital Civic Campus	Ottawa	Ontario
Canada	Ottawa Hospital General Campus	Ottawa	Ontario
Canada	Hopital de l'Enfant-Jesus	Quebec
Canada	St Michael's Hospital	Toronto	Ontario
Canada	St. Boniface Hospital	Winnipeg	Manitoba
Canada	Winnipeg Health Sciences Centre	Winnipeg	Manitoba

Sponsors (1)

Lead Sponsor	Collaborator
University of Manitoba

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of enrollment - to enrol an average of 2 patients per site per month over the duration of the study	The primary measure of feasibility is the ability of participating sites to enroll an average of 2 patients per month.	1 year	No
Secondary	Feasibility(1) - Consent rate - will be considered adequate if 60% of eligible patients are enrolled in the HALO pilot		1 year	No
Secondary	Safety - Rate of major and minor bleeding events	a.) Rates of major and minor bleeding will be adjudicated and will be considered in the context of monitored aPTTs: 1) in the context of aPTTs =95 seconds, the rate of major bleeding will be deemed acceptable if major bleeding occurs in =10% of patients; and 2) if >20% of patients require an initial (6 hour aPTT) dose reduction of the study drug due to an aPTT >95 seconds, this dose will be deemed infeasible as an initiation dose.	Duration of ICU admission, or up to day +9	Yes
Secondary	Activation of coagulation - Thrombin-antithrombin (TAT) complexes		Day 1, 2, 3, 5, 7, and 9 (or ICU discharge)	No
Secondary	Feasibility(2): Protocol Deviations - The investigators believe that an acceptable rate of protocol violations resulting in a non-scheduled dose reduction or interruption of the study drug to be less than 10% of all study drug dose adjustments		Duration of study drug infusion or up to a maximum of 7 days	No
Secondary	Feasibility(3) - Time from randomization to initiation of study drug	The investigators will consider the time from randomization to study treatment initiation to be satisfactory if this interval is less than 4 hours.	the outcome will be assessed during the first 24 hours of enrollment	No
Secondary	Activation of coagulation - Protein C concentration		Day 1, 2, 3, 5, 7, and 9 (or ICU discharge)	No
Secondary	Activation of Coagulation - Quantitative d-dimer		Days 1, 2, 3, 5, 7, and 9 (or ICU discharge)	No
Secondary	Markers of Inflammation (IL-6, IL-8, IL-10, and IL-17)		Days 1, 2, 3, 5, 7, and 9 (or ICU discharge)	No
Secondary	ICU Mortality (Tertiary, descriptive outcome only)		Will be assessed at the time of ICU discharge or death; expected average length of ICU admission is 5.7 days	No
Secondary	Hospital Mortality (Tertiary, descriptive outcome only)		Will be assessed at the time of hospital discharge or death; expected average length of hospital admission is 14 days	No
Secondary	Change in MODS score (Tertiary, descriptive outcome only)		Will be assessed daily during admission to the ICU; expected average length of ICU admission is 5.7 days	No